The role of basiliximab induction therapy in organ transplantation

Bibliography

• FERGUSON R: Acute rejection episodes- best predictor of long term primary cadaveric renal transplant survival. Clin. Transplant. (1994) 8:328-331.
   PubMed Web of Science ®Google Scholar
• SANDRINI S: Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin. Transplant. (2005) 19:705-710.
   PubMed Web of Science ®Google Scholar
• BRENNAN DC: Action, efficacy and toxicities: polyclonal anti-lymphocyte antibodies. In: Primer on Transplantation (2nd Edn). Norman DJ, Turka LA (Eds), Mt Laurel, NJ, American Society of Transplantation (2001):152.
   Google Scholar
• MORGAN DA, RUSCETTI FW, GALLO RC: Selective in vitro growth of T-lymphocytes from human bone marrow. Science (1976) 193:1007-1008.
   PubMed Web of Science ®Google Scholar
• ROB RJ, GREENE WC, RUSK CM: Low and high affinity cellular receptors for interleukin 2: implications for the level of Tac antigen. J. Exp. Med. (1984) 160:1126-1146.
   PubMed Web of Science ®Google Scholar
• FELDMANN F: Cell cooperation in the antibody response. In: Immunology (4th Edn). Roitt I, Bronstoff J, Male D (Eds), Times Mirror International Publishers, London, UK (1996):8.1-8.16.
   Google Scholar
• UCHIYAMA T, NELSON DL, FLEISHER TA, WALDMANN TA: A monoclonal antibody (anti-TAC) reactive with activated and functionally mature human T-cells. J. Immunol. (1981) 126:1398-1403.
   PubMed Web of Science ®Google Scholar
• STROM TB, KELLEY VR, MURPHY JR et al.: Interleukin-2 receptor directed therapies. Annu. Rev. Med. (1993) 44:343-353.
   PubMed Web of Science ®Google Scholar
• LOBUGLIO AF, WHEELER RH, TRANG J et al.: Mouse/human chimeric monoclonal antibodies in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA (1989) 86:4220-4224.
   PubMed Web of Science ®Google Scholar
• CIBRIK DM, KAPLAN B, MEIER-KRIESCHE H-U: Role of anti-interleukin 2 receptor antibodies in kidney transplantation. Biodrugs (2001) 15:655-666.
   PubMed Web of Science ®Google Scholar
• WILLIAMS KA, THIEL M, ZOLA H: The new generation anti-CD25 monoclonal antibodies. Transplantation (1999) 68:1228-1229.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, LANTZ M, BIRNBAUM J et al.: A Phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation (1997) 63:33-38.
   PubMed Web of Science ®Google Scholar
• AMLOT PL, RAWLINGS E, FERNANDO ON et al.: Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation (1995) 60:748-756.
   PubMed Web of Science ®Google Scholar
• NASHAN B, MOORE R, AMLOT P, SCHMIDT A, KAMAL A, SOULLILLOU JP: Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet (1997) 350:1193-1198.
   PubMed Web of Science ®Google Scholar
• KOVARIK J, WOLF P, CISTERNE JM et al.: Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation (1997) 64:1701-1705.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, RAWLINGS E, SWENY O et al.: Prolonged immunosuppressive effect and minimal immunogenecity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant. Proc. (1996) 28:913-914.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, RAWLINGS E, SWENY P et al.: Pharmacokinetics and immuno-dynamics of chimeric IL-2 receptor monoclonal antibody SDZCHI621 in renal allograft recipients. Transplant. Int. (1996) 9(Suppl. 1):32-33.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, MOORE R, WOLF P et al.: Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin. Transplant. (1999) 13:32-38.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, KAHAN BD, RAJAGOPALAN PR et al.: Population pharmaco-kinetics and exposure- response relationships for basiliximab in kidney transplantation. The US Simulect Renal Transplant Study Group. Transplantation (1999) 68:1288-1294.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, NASHAN B, NEUHAUS P et al.: A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin. Pharmacol. Ther. (2001) 69:201-209.
   Google Scholar
• KOVARIK JM, BREIDENBACH T, GERBEAU C et al.: Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin. Pharmacol. Ther. (1998) 64:66-72.
   Google Scholar
• KOVARIK J, MENTSER M, BROYER P et al.: Disposition of basiliximab, a chimeric IL-2 receptor (CD25) monoclonal antibody, in pediatric renal transplant patients (abstract 254). Transplantation (1998) 65:S66.
   Google Scholar
• KOVARIK JM, GRIDELLI BG, MARTIN S et al.: Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr. Transplant. (2002) 6:224-230.
   Google Scholar
• KOVARIK JM, OFFNER G, BROYER M et al.: A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmaco-kinetic–dynamic evaluations. Transplantation (2002) 74:966-971.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, RAJAGOPALAN PR, HALL M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody. Transplantation (1999) 67:276-284.
   PubMed Web of Science ®Google Scholar
• HABA T, UCHIDA K, KATAYAMA A et al.: Pharmacokinetics and pharmaco-dynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients. Transplant. Proc. (2001) 33(7-8):3174-3175.
   PubMed Web of Science ®Google Scholar
• BASADONNA GP, MATAS AJ, GILLINGHAM KJ et al.: Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation (1993) 55:993-995.
   PubMed Web of Science ®Google Scholar
• WEBSTER A, PLAYFORD E, HIGGINS G et al.: Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 77:166-176.
   PubMed Web of Science ®Google Scholar
• KEOWN P, BALSHAW R, KHORASHEH S et al.: Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. Biodrugs (2003) 17:271-279.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, YUSSIM A, CAMBI V et al.: A randomized double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 72:1261-1267.
   PubMed Web of Science ®Google Scholar
• LAWEN JG, DAVIES EA, MOURAD G et al.: Randomized double-blind study of immunoprophylaxis with Basiliximab, an anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation (2003) 75:37-43.
   PubMed Web of Science ®Google Scholar
• KUMAR M, KODE R, PANKEWYCZ O et al.: Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function (DGF): a prospective controlled study. Transplant. Proc. (2001) 33:3762-3763.
   Web of Science ®Google Scholar
• PHILOSOPHE B, FINK JC, WILAND AM et al.: Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function. Transplantation (2000) 69:S259.
   Google Scholar
• HARIRIAN A, MORAWSKI K, SILLIX DH et al.: Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation (2005) 79:716-721.
   PubMed Web of Science ®Google Scholar
• WILAND AM, FINK JC, WEIR MR et al.: Should living unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation (2004) 77:422-425.
   PubMed Web of Science ®Google Scholar
• CLARK G, WALSH G, DESHPANDE P et al.: Improved efficacy of basiliximab over anti- lymphocyte globulin induction therapy in pediatric renal transplantation. Nephrol. Dial. Transplant. (2002) 17:1304-1309.
   Web of Science ®Google Scholar
• MONTINI G, MURER L, GHIO L et al.: One year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transplant. Int. (2005) 18:36-42.
   PubMed Web of Science ®Google Scholar
• OFFNER G, BROYER M, NIAUDET P et al.: A multi-center open label, pharmacokinetic/pharmacodynamic safety and tolerability study of basiliximab (simulect) in pediatric de novo renal transplant recipients. Transplantation (2002) 74:961-966.
   PubMed Web of Science ®Google Scholar
• SWIATECKA-URBAN A, GARCIA C, FEURSTEIN D et al.: Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr. Nephrol. (2001) 16:693-696.
   PubMed Web of Science ®Google Scholar
• VESTER U, KRANZ B, TESTA G et al.: Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr. Transplant. (2001) 5:297-301.
   PubMed Web of Science ®Google Scholar
• ACOTT P, LAWEN J, CROCKER J: Third dose of basiliximab in pediatric renal transplantation. Transplant. Proc. (2004) 36:2628-2631.
   PubMed Web of Science ®Google Scholar
• PAPE L, STREHLAU J, HENNE T et al.: Single center experience with basiliximab in pediatric renal transplant recipients. Pediatr. Transplant. (2001) 5:297-301.
   PubMed Web of Science ®Google Scholar
• GARCIA MC, VILLALOPEZ A, LUQUE DE PABLOS A et al.: Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units. Transplant. Proc. (2003) 35:1697-1698.
   PubMed Web of Science ®Google Scholar
• DUZOVA A, BUYAN N, BAKKALOGLU M et al.: Triple immunosuppressioin with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant. Proc. (2003) 35:2878-2880.
   PubMed Web of Science ®Google Scholar
• SHAPIRO R, YOUNG JB, MILFORD EL, TROTTER JF, BUSTAMI RT, LEICHTMAN AB: Immunosuppression: evolution in practice and trends, 1993-2003. Am. J. Transpl. (2005) 5(2):874-886.
   PubMed Web of Science ®Google Scholar
• NEUHAUS P, CLAVIEN PA, KITTUR D et al.: Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double blind randomized placebo controlled trial. Liver Transpl. (2002) 8:132-142.
   PubMed Web of Science ®Google Scholar
• CALMUS Y, SCHEELE JR, GONZALEZ-PINTO I et al.: Immunoprophylaxis with basiliximab, a chimeric interleukin 2 receptor monoclonal antibody, in combination with azathioprine- containing triple therapy in liver transplant recipients. Liver Transpl. (2002) 8:123-131.
   PubMed Web of Science ®Google Scholar
• GRANNAS G, LUECK R, BECKER T et al.: Immunoprophylaxis with Simulect (basiliximab) in combination with cyclosporine and steroids in liver transplantation. Proceedings of the Transplant 2001 Meeting. Chicago, IL, USA (11 – 16 May 2001).
   Google Scholar
• MARINO IR, DORIA C, SCOTT V et al.: Efficacy and safety of basiliximab with a tacrolimus based regimen in liver transplant recipients. Transplantation (2004) 78:886-891.
   PubMed Web of Science ®Google Scholar
• REDING R, GRAS J, SOKAL E et al.: Steroid free liver transplantation in children. Lancet (2003) 362:2068-2070.
   PubMed Web of Science ®Google Scholar
• GANSCHOW R, GRABHORN E, SCHULZ A et al.: Long term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr. Transplant. (2005) 9:741-745.
   PubMed Web of Science ®Google Scholar
• ELKHAMMAS EA, HENRY MI, DEMIRAG A et al.: Basiliximab versus OKT3 in primary simultaneous pancreas-kidney transplant recipients. Transplantation (2000) 69:S407.
   Google Scholar
• CHOW FY, POLKINGHORNE K, SAUNDER A, KERR PG, ATKINS RC, CHADBAN SJ: Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrology (2003) 8:212-216.
   PubMed Web of Science ®Google Scholar
• HESSE UJ, TROISI R, JACOBS B et al.: A single center’s clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin. Transplant. (2000) 14:340-341.
   PubMed Web of Science ®Google Scholar
• MEHRA MR, ZUCKER MJ, WAGONER L et al.: A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J. Heart Lung Transplant. (2005) 24:1297-304.
   PubMed Web of Science ®Google Scholar
• BORRO J, DE LA TORRE M, MIGUELEZ C et al.: Comparative study of basiliximab treatment in lung transplantation. Transplant. Proc. (2005) 37:3996-3998.
   PubMed Web of Science ®Google Scholar
• DE LA TORRE M, PENA E, CALVIN M et al.: Basiliximab in lung transplantation: preliminary experience. Transplant. Proc. (2005) 37:1534-1536.
   PubMed Web of Science ®Google Scholar
• HACHEM RR, CHAKINALA MM, YUSEN RD et al.: A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J. Heart Lung Transplant. (2005) 24:1320-1326.
   PubMed Web of Science ®Google Scholar
• VINCENTI F: The role of newer monoclonal antibodies in renal transplantation. Transplant. Proc. (2001) 33:1000-1001.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, GERBEAU C, LEGAY F et al.: Clinical impact of chimerization on immunogenicity of T-cell antigen monoclonal antibodies in renal transplantation (abstract no. 253). Transplantation (1998) 65(Suppl. 1):142.
   PubMed Web of Science ®Google Scholar
• BAUDOUIN V, CRUSIAUX A, HADDAD E et al.: Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation (2003) 76:459-463.
   PubMed Web of Science ®Google Scholar
• BARROS VR, ROCHA V, GARCIA VD et al.: Anaphylactic shock after retreatment with basiliximab. Transplant. Proc. (2003) 35:579.
   PubMedGoogle Scholar
• LEONARD PA, WOODSIDE KJ, GUGLIUZZA KK, SUR S, DALLER JA: Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation (2002) 74:1697-1700.
   PubMed Web of Science ®Google Scholar
• SOLLINGER H, KAPLAN B, PESKOVITZ MD et al.: Basiliximab versus anti-thymocyte globulin for prevention of acute renal allograft rejection. Transplantation (2001) 72:1915-1919.
   PubMed Web of Science ®Google Scholar
• LEBRANCHU Y, BRIDOUX F, BUCHLER M et al.: Basiliximab versus antithymocyte globulin in renal transplantation. Am. J. Transplant. (2002) 2:48-56.
   PubMed Web of Science ®Google Scholar
• MOURAD G, ROSTAING L, LEGENDRE C et al.: Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation (2004) 78:584-590.
   PubMed Web of Science ®Google Scholar
• HARADA MM, FUKUZAWA N, IWAMI D et al.: Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil, and prednisone is safe and effective for renal transplantation. Clin. Transplant. (2005) 19(Suppl. 14):54-58.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, MONACO A, GRINYO J et al.: Multi-center randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am. J. Transplant. (2003) 3:306.
   PubMed Web of Science ®Google Scholar
• VITKO S, KLINGER M, SALMELA K et al.: Two corticosteroid-free regimens- tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil- in comparison with a standard triple regimen in renal transplantation: results of the atlas study. Transplantation (2005) 80:1734-1741.
   PubMed Web of Science ®Google Scholar
• WOODLE ES, VINCENTI F, LORBER M et al.: A multi-center open label pilot study of early (5 day) corticosteroid cessation in de novo renal transplant recipients under Simulect, tacrolimus and sirolimus therapy. Am. J. Transplant. (2005) 5:157-166.
   PubMed Web of Science ®Google Scholar
• KUMAR MS, HEIFETS M, MORITZ MJ et al.: Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation (2006) 81:832-839.
   PubMed Web of Science ®Google Scholar
• KUMAR MS, XIAO SG, FYFE B et al.: Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin. Transplant. (2005) 19:61-69.
   PubMed Web of Science ®Google Scholar
• KUMAR MS, MORITZ MJ, SAAED MI et al.: Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am. J. Transplant. (2005) 5:1976-1985.
   PubMed Web of Science ®Google Scholar
• PAGEAUX GP, CALMUS Y, BOILLOT O et al.: Steroid withdrawal at day 14 after liver transplantation: a double blind, placebo controlled study. Liver Transpl. (2004) 10:1454-1460.
   PubMed Web of Science ®Google Scholar
• LIU CL, FAN ST, LO CM et al.: Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. (2004) 10:728-733.
   PubMed Web of Science ®Google Scholar
• LLADO L, XIOL X, FIGUERAS J et al.: Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J. Hepatol. (2006) 44:710-716.
   PubMed Web of Science ®Google Scholar
• CANTAROVICH M, METRAKOS P, GIANNETTI N et al.: Anti-CD 25 monoclonal antibody coverage allows for calcineurin inhibitor ‘holiday’ in solid organ transplant patients with acute renal dysfunction. Transplantation (2002) 73:1169-1172.
   PubMed Web of Science ®Google Scholar
• DELGADO DH, MIRIUKA SG, CUSIMANO RJ et al.: Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J. Heart Lung Transplant. (2005) 24:166-169.
   PubMed Web of Science ®Google Scholar
• ROSENBERG PB, VRIESENDORP AE, DRAZNER MH et al.: Induction therapy with basiliximab allows initiation of cyclosporine and preserves renal function after cardiac transplantation. J. Heart Lung Transplant. (2005) 24:1327-1331.
   PubMed Web of Science ®Google Scholar
• LIN CC, CHUANG FR, LEE CH et al.: The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl. (2005) 11:1258-1264.
   PubMed Web of Science ®Google Scholar
• TRAN HT, ACHARYA MK, MCKAY DB et al.: Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J. Am. Soc. Nephrol. (2000) 11:1903-1909.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, RAMOS E, BRATSTROM C et al.: Multi-center trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 71:1282-1287.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, GRINYO J, RAMOS E et al.: Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant. Proc. (1999) 31:1246-1248.
   Web of Science ®Google Scholar
• YOUNES BS, MCDIARMID SV, MARTIN MG et al.: The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation (2000) 70:94-99.
   PubMed Web of Science ®Google Scholar
• AW MM, TAYLOR RM, VERMA A et al.: Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: a preliminary experience. Transplantation (2003) 75:796-99
   PubMed Web of Science ®Google Scholar
• LORBER MI, FASTENAU J, WILSON D et al.: A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin. Transplant. (2000) 14:479-485.
   PubMed Web of Science ®Google Scholar
• KEOWN PA, BALSHAW R, KRUEGER H et al.: Economic analysis of basiliximab in renal transplantation. Transplantation (2001) 71:1573-1579.
   PubMed Web of Science ®Google Scholar
• WALTERS SJ, WHITFIELD M, AKERHURST RL et al.: Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients. Pharmacoeconomics (2003) 21:129-138.
   PubMed Web of Science ®Google Scholar
• WALTERS SJ, WHITFIELD M, AKEHURST RL et al.: Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. Transplant. Proc. (2001) 33:3187-3191.
   Web of Science ®Google Scholar
• POLSKY D, WEINFURT KP, KAPLAN B et al.: An economic and quality of life assessment of basiliximab versus antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol. Dial. Transplant. (2001) 16:1028-1033.
   PubMed Web of Science ®Google Scholar
• LILLIU H, BRUN-STRANG C, LE PEN C et al.: Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction. Clin. Transplant. (2004) 18:247-253.
   PubMed Web of Science ®Google Scholar